Patents by Inventor Lioudmila Tchistiakova
Lioudmila Tchistiakova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117030Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.Type: ApplicationFiled: February 28, 2023Publication date: April 11, 2024Inventors: Rita Diane AGOSTINELLI, James Reasoner APGAR, Eric Matthew BENNETT, Laird BLOOM, Ting CHEN, Aaron Michael D'ANTONA, Arnab DE, Fang JIN, Marion Teresa KASAIAN, Matthew Allister LAMBERT, Kimberly Ann MARQUETTE, Virginie MCMANUS, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Richard Thomas SHELDON, Lioudmila TCHISTIAKOVA, Alexander Michael Shuford BARRON, Richard Lee GIESECK, III, Xiaotian ZHONG
-
Publication number: 20240059799Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.Type: ApplicationFiled: May 9, 2023Publication date: February 22, 2024Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
-
Patent number: 11692025Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: GrantFiled: May 17, 2021Date of Patent: July 4, 2023Assignee: ELASMOGEN LIMITEDInventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
-
Patent number: 11578428Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.Type: GrantFiled: April 1, 2020Date of Patent: February 14, 2023Assignee: Pfizer Inc.Inventors: William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
-
Publication number: 20210332116Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: ApplicationFiled: May 17, 2021Publication date: October 28, 2021Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
-
Patent number: 11147852Abstract: The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C?, C?, and C?) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.Type: GrantFiled: December 19, 2012Date of Patent: October 19, 2021Assignee: Pfizer Inc.Inventors: Kimberly Marquette, Eric Bennett, Lioudmila Tchistiakova, L. Nathan Tumey, Jack Bikker, Valerie Calabro, Edmund Graziani
-
Patent number: 11034756Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: GrantFiled: March 8, 2019Date of Patent: June 15, 2021Assignee: ELASMOGEN LIMITEDInventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
-
Publication number: 20210040182Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.Type: ApplicationFiled: April 1, 2020Publication date: February 11, 2021Inventors: William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
-
Patent number: 10647756Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.Type: GrantFiled: May 16, 2016Date of Patent: May 12, 2020Assignee: Pfizer Inc.Inventors: William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
-
Publication number: 20200123260Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: ApplicationFiled: June 26, 2019Publication date: April 23, 2020Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Publication number: 20200069764Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.Type: ApplicationFiled: November 19, 2019Publication date: March 5, 2020Applicant: Pfizer Inc.Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
-
Patent number: 10392438Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: GrantFiled: May 13, 2015Date of Patent: August 27, 2019Assignee: PFIZER INC.Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Publication number: 20190194307Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: ApplicationFiled: March 8, 2019Publication date: June 27, 2019Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
-
Patent number: 10287341Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: GrantFiled: September 22, 2016Date of Patent: May 14, 2019Assignee: The University Court of the University of AberdeenInventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
-
Publication number: 20180179285Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.Type: ApplicationFiled: May 13, 2015Publication date: June 28, 2018Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
-
Publication number: 20180162937Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Applicant: WYETH LLCInventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
-
Patent number: 9926368Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: January 22, 2015Date of Patent: March 27, 2018Assignee: Wyeth LLCInventors: Frank S. Walsh, Margaret M. Zaleska, David S. Howland, Lioudmila Tchistiakova, Riyez Karim, Pamela Kelley, Xiang-Yang Tan, Seung Poon Kwak, Menelas N. Pangalos
-
Patent number: 9902771Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: GrantFiled: December 16, 2015Date of Patent: February 27, 2018Assignee: WYETH LLCInventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Sreekumar R. Kodangattil
-
Publication number: 20170216452Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.Type: ApplicationFiled: November 21, 2016Publication date: August 3, 2017Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
-
Patent number: 9644025Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.Type: GrantFiled: October 17, 2008Date of Patent: May 9, 2017Assignees: WYETH LLC, JANSSEN SCIENCES IRELAND UCInventors: Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom